Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract
Status:
Withdrawn
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well methylprednisolone sodium succinate works in treating
patients with graft-versus-host disease (GVHD) of the gastrointestinal tract that has begun
within 100 days of transplant (acute GVHD). Corticosteroids are a type of drug that reduces
inflammation. Giving corticosteroid drugs, such as methylprednisolone sodium succinate,
directly into the arteries of the gastrointestinal tract may help treat inflammation caused
by GVHD. Giving methylprednisolone sodium succinate in addition to standard treatments may be
more effective in treating GVHD.